Cargando…

Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis

In China, hepatocellular carcinoma (HCC) usually develops following a long history of chronic hepatitis B infection or cirrhosis. To evaluate the diagnostic role of annexin A2 (ANXA2), a possible tumor marker, in patients with hepatitis B virus (HBV)-related HCC, particularly those with a history of...

Descripción completa

Detalles Bibliográficos
Autores principales: LIU, ZHIKUN, LING, QI, WANG, JIANGUO, XIE, HAIYANG, XU, XIAO, ZHENG, SHUSEN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742823/
https://www.ncbi.nlm.nih.gov/pubmed/23946789
http://dx.doi.org/10.3892/ol.2013.1337
_version_ 1782280420713299968
author LIU, ZHIKUN
LING, QI
WANG, JIANGUO
XIE, HAIYANG
XU, XIAO
ZHENG, SHUSEN
author_facet LIU, ZHIKUN
LING, QI
WANG, JIANGUO
XIE, HAIYANG
XU, XIAO
ZHENG, SHUSEN
author_sort LIU, ZHIKUN
collection PubMed
description In China, hepatocellular carcinoma (HCC) usually develops following a long history of chronic hepatitis B infection or cirrhosis. To evaluate the diagnostic role of annexin A2 (ANXA2), a possible tumor marker, in patients with hepatitis B virus (HBV)-related HCC, particularly those with a history of cirrhosis, the present study prospectively enrolled 87 patients with HBV-related HCC (with cirrhosis), 39 patients with HBV-related cirrhosis and 27 healthy controls. The expression levels of serum and tissue ANXA2 were determined using an enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining, respectively. The serum levels of ANXA2 were significantly elevated in the patients with HCC (median, 567.2 μg/ml; P=0.003) and cirrhosis (median, 414.8 μg/ml; P=0.011) compared with the healthy controls (median, 241.9 μg/ml). However, no significant differences were observed in the serum ANXA2 levels between the patients with HCC and those with cirrhosis. The immunohistochemical staining analysis showed that the healthy controls did not show positive staining, while the number of cases immunoreactive for ANXA2 steadily increased from the liver cirrhosis tissues (20/39, 51.3%) to the non-cancer (53/87, 60.9%) and cancer tissues (68/87, 78.2%). The cancer tissues exhibited a significantly higher ANXA2-positive rate compared with the non-cancer (P=0.013) and liver cirrhosis tissues (P=0.002). Furthermore, marked ANXA2 staining was more prevalent in the cancer tissues (16/87, 18.4%) than the non-cancer (4/87, 4.6%; P=0.004) and liver cirrhosis (1/39, 2.6%; P=0.034) tissues. The sensitivity, specificity and diagnostic accuracy of tissue ANXA2 for HCC in cirrhosis were 78.2, 42.1 and 56.8%, respectively. The ANXA2 expression levels in the serum and cancer tissues were not associated with tumor-free survival or patient survival following liver transplantation. Serum or tissue ANXA2 is not a good diagnostic marker for HCC in HBV-related cirrhosis and is not associated with prognosis.
format Online
Article
Text
id pubmed-3742823
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-37428232013-08-14 Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis LIU, ZHIKUN LING, QI WANG, JIANGUO XIE, HAIYANG XU, XIAO ZHENG, SHUSEN Oncol Lett Articles In China, hepatocellular carcinoma (HCC) usually develops following a long history of chronic hepatitis B infection or cirrhosis. To evaluate the diagnostic role of annexin A2 (ANXA2), a possible tumor marker, in patients with hepatitis B virus (HBV)-related HCC, particularly those with a history of cirrhosis, the present study prospectively enrolled 87 patients with HBV-related HCC (with cirrhosis), 39 patients with HBV-related cirrhosis and 27 healthy controls. The expression levels of serum and tissue ANXA2 were determined using an enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining, respectively. The serum levels of ANXA2 were significantly elevated in the patients with HCC (median, 567.2 μg/ml; P=0.003) and cirrhosis (median, 414.8 μg/ml; P=0.011) compared with the healthy controls (median, 241.9 μg/ml). However, no significant differences were observed in the serum ANXA2 levels between the patients with HCC and those with cirrhosis. The immunohistochemical staining analysis showed that the healthy controls did not show positive staining, while the number of cases immunoreactive for ANXA2 steadily increased from the liver cirrhosis tissues (20/39, 51.3%) to the non-cancer (53/87, 60.9%) and cancer tissues (68/87, 78.2%). The cancer tissues exhibited a significantly higher ANXA2-positive rate compared with the non-cancer (P=0.013) and liver cirrhosis tissues (P=0.002). Furthermore, marked ANXA2 staining was more prevalent in the cancer tissues (16/87, 18.4%) than the non-cancer (4/87, 4.6%; P=0.004) and liver cirrhosis (1/39, 2.6%; P=0.034) tissues. The sensitivity, specificity and diagnostic accuracy of tissue ANXA2 for HCC in cirrhosis were 78.2, 42.1 and 56.8%, respectively. The ANXA2 expression levels in the serum and cancer tissues were not associated with tumor-free survival or patient survival following liver transplantation. Serum or tissue ANXA2 is not a good diagnostic marker for HCC in HBV-related cirrhosis and is not associated with prognosis. D.A. Spandidos 2013-07 2013-05-08 /pmc/articles/PMC3742823/ /pubmed/23946789 http://dx.doi.org/10.3892/ol.2013.1337 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
LIU, ZHIKUN
LING, QI
WANG, JIANGUO
XIE, HAIYANG
XU, XIAO
ZHENG, SHUSEN
Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
title Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
title_full Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
title_fullStr Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
title_full_unstemmed Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
title_short Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
title_sort annexin a2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742823/
https://www.ncbi.nlm.nih.gov/pubmed/23946789
http://dx.doi.org/10.3892/ol.2013.1337
work_keys_str_mv AT liuzhikun annexina2isnotagoodbiomarkerforhepatocellularcarcinomaincirrhosis
AT lingqi annexina2isnotagoodbiomarkerforhepatocellularcarcinomaincirrhosis
AT wangjianguo annexina2isnotagoodbiomarkerforhepatocellularcarcinomaincirrhosis
AT xiehaiyang annexina2isnotagoodbiomarkerforhepatocellularcarcinomaincirrhosis
AT xuxiao annexina2isnotagoodbiomarkerforhepatocellularcarcinomaincirrhosis
AT zhengshusen annexina2isnotagoodbiomarkerforhepatocellularcarcinomaincirrhosis